Massachusset, USA-based global women’s health medtech, Biorithm closed Series A financing with USD 3.5 million. Adaptive Capital Partners and SEEDS Capital led the financing for the company. The company announced the investment on December 18, 2023.
Purpose of financing for Biorithm
With the latest financing, Biorithm seeks to fuel its expansion in Southeast Asia as well as the United States. It also will assist the company in advancing Femom, a comprehensive obstetric remote monitoring solution. Meanwhile, the company has plans to complete clinical studies to support a 510(K) premarket submission to the US Food and Drug Administration.
In addition, the funds from Adaptive Capital Partners and existing investor SEEDS Capital bolster their recognition of Biorithm’s pivotal role in reshaping women’s healthcare through innovative technology.
What the company’s official has to add
Julian Robinson, Chairman of Biorithm Medical Advisory Board, said, “Biorithm will enhance care, minimize inconvenience, reduce cost for patients and improve the efficiency and effectiveness of the clinical health care provider. Above all, it will improve medical outcomes for mothers and their babies.”
Amrish Nair, Founder and CEO of Biorithm, further said, “We are truly heartened to have the support of our new and existing investors. We feel a deep commitment to improving the health of expectant mothers and putting an end to preventable complications. There is a collapse of maternal care driven by socio-economic factors and limitations of current monitoring technologies in many regions across the world, and we are hard at work to solve this problem in partnership with others. The investment we have received is a testament to our mission at Biorithm and a future where every expectant mother has access to healthcare that is not only proactive but profoundly connected to her unique journey.”
What the investors have to comment
Shi Ying, Founder & Managing Partner of Adaptive Capital Partners, said, “Building a system of connected medical care is crucial to help clinicians predict, diagnose, and formulate calculated decisions on early intervention to prevent complications and devise treatments. We are excited with our investment into Biorithm as the company is focused on creating measurable and actionable value in maternal health, integrating this system across all touchpoints to ensure safety throughout the pregnancy journey.”
In addition, Tan Kaixin, General Manager, SEEDS Capital, added, “By leveraging technology to enable remote monitoring, Biorithm’s offering provides enhanced access to quality care for expectant mothers. We are excited to continue backing Biorithm as they accelerate their commercialization in the US and support their vision of revolutionizing the global maternal health market. Investments in MedTech startups like Biorithm will propel the healthcare ecosystem to new heights.”
About Biorithm
Amrish Nair, David Foo, and Pina Marziliano launched the company in 2015. Biorithm envisions a world with better access to maternal care and improved outcomes for mother and child.
To explore more such startups, visit Zefyron Startup Database
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
